Jerrold B. Grossman - 09 Jun 2025 Form 4 Insider Report for ADMA BIOLOGICS, INC. (ADMA)

Role
Director
Signature
/s/ Dr. Jerrold B. Grossman, by Adam S. Grossman as Attorney-in-fact
Issuer symbol
ADMA
Transactions as of
09 Jun 2025
Net transactions value
-$163,100
Form type
4
Filing time
10 Jun 2025, 21:00:32 UTC
Previous filing
21 Feb 2025
Next filing
11 Feb 2026

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Grossman Jerrold B Director C/O ADMA BIOLOGICS, INC., 465 STATE ROUTE 17, RAMSEY /s/ Dr. Jerrold B. Grossman, by Adam S. Grossman as Attorney-in-fact 10 Jun 2025 0001542519

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ADMA Common Stock Options Exercise $50,000 +10,000 +2.1% $5.00 488,194 09 Jun 2025 Direct
transaction ADMA Common Stock Sale $213,100 -10,000 -2% $21.31 478,194 09 Jun 2025 Direct F1, F2
holding ADMA Common Stock 22,857 09 Jun 2025 See footnote F3
holding ADMA Common Stock 31,381 09 Jun 2025 See footnote F4
holding ADMA Common Stock 38,294 09 Jun 2025 See footnote F5
holding ADMA Common Stock 175 09 Jun 2025 See footnote F6

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ADMA Stock Option (right to buy) Options Exercise $0 -10,000 -100% $0.000000 0 09 Jun 2025 Common Stock 10,000 $5.00 Direct F7
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.29 to $21.35. The reporting person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.
F2 Includes, as of the transaction date, (i) 10,889 restricted stock units granted on February 19, 2025, which will vest in full on February 19, 2026, subject to the Reporting Person's continued service as of the applicable vesting date; and (ii) 467,305 shares of common stock owned by the reporting person.
F3 These shares are owned by Brookwood LLC ("Brookwood"). The reporting person is the managing member of Brookwood.
F4 These shares are owned by the Jerrold Grossman 2019 Irrevocable Trust, of which Dr. Grossman serves as investment trustee.
F5 These shares are owned by Genesis Foundation Inc. ("Genesis"). The reporting person is the President of Genesis.
F6 These shares are owned by the reporting person's wife.
F7 These options were granted on February 14, 2017 and vested in twenty-four equal monthly installments, becoming fully vested on February 14, 2019.